Objective To evaluate the efficacy, safety and feasibility of autologous concentrated growth factor (CGF) scalp intradermal injection for female androgenetic alopecia (AGA). Methods A total of 60 female AGA patients enrolled from August 2023 to January 2025 were equally assigned into the treatment group and the control group. The treatment group received autologous CGF intradermal scalp injection, while the control group was treated with conventional minoxidil tincture. Results? All patients completed the follow-up. After 4 months of intervention, the symptoms of folliculitis, scalp sebum secretion, dandruff and pruritus were significantly improved in both groups (P<0.05), with better improvements in the treatment group (P<0.05). There were significant intergroup differences in hair density, mean hair diameter and terminal/vellus hair ratio (P<0.05). The control group showed significant improvements only in hair density and mean diameter (P<0.05), with no significant change in terminal/vellus hair ratio (P>0.05). The treatment group achieved significant improvements in all three morphological indicators, which were superior to those of the control group. The patient satisfaction rate was 100% in the treatment group, significantly higher than 83.3% in the control group (P=0.002). Conclusion Intradermal scalp injection of CGF can effectively alleviate hair loss symptoms, scalp sebum secretion, folliculitis and pruritus in patients with AGA. With high safety and easy operation, it can be adopted as a novel therapy for AGA.